Recent articles

Chemkart India's initial public offering (IPO) has demonstrated steady investor demand through its third and final day of subscription, with Chemkart India's stock price set at ₹248 per share reflecting measured market reception. The ₹80.08 crore IPO reached 5.91 times by 5:04:33 PM on day three, indicating solid investor interest in this food and health ingredients distributor incorporated in 2015. Chemkart India IPO qualified institutional buyers segment leads with robust 13.69 times subscription, whilst non-institutional investors demonst

Smarten Power Systems' initial public offering (IPO) has demonstrated solid investor demand through its third and final day of subscription, with Smarten Power Systems' stock price set at ₹100 per share reflecting positive market reception. The ₹50.00 crore IPO reached 5.51 times by 5:09:59 PM on day three, indicating reasonable investor interest in this power backup and solar products company incorporated in 2014. Smarten Power Systems IPO non-institutional investors segment leads with strong 6.31 times subscription, whilst individual inves

The SBI Nifty100 Low Volatility 30 Index Fund is an open-ended index fund that aims to replicate the performance of the Nifty100 Low Volatility 30 Index. This index is composed of 30 stocks selected from the Nifty100 based on their low volatility, making it a more stable option for long-term investors. The fund adopts a passive investment approach, meaning it does not actively try to outperform the index but mirrors its composition and returns, subject to tracking error. It suits investors who are looking for a cost-effective and diversified eq

The ICICI Pru Active Momentum Fund is an open-ended thematic equity scheme focused on momentum investing. It aims to deliver long-term capital appreciation by investing in equity and equity-related instruments of companies that exhibit strong momentum traits. This includes price momentum and earnings momentum, identified through proprietary models that assess past trends and analyst revisions. The fund applies filters for risk and governance, ensuring a well-curated portfolio of high-potential companies. With dynamic rebalancing, diversificatio

In a move that could reshape index derivatives trading in India, the Securities and Exchange Board of India (SEBI) is reportedly considering a shift from the current weekly expiry system to a fortnightly schedule. This potential reform comes amid efforts by the regulator to control the booming activity in the index options segment, especially among retail investors. According to a Mint report published on July 9, the regulator may introduce a fortnightly expiry format or reduce the frequency to a single benchmark index expiry per fortnight.

India's initial public offering (IPO) market is anticipating a busy second half of 2025 as a number of well-known companies prepare to go public. Tata Capital, LG Electronics India, and National Securities Depository Ltd (NSDL) are at the top of the pack and are all expected to introduce big issues to the stock exchanges in the upcoming months. According to a recent Axis Capital update, 71 companies have already obtained regulatory permission from SEBI, while another 77 are in the queue. This robust pipeline indicates a market ready for new

Retail investors showed increased interest in mutual funds during June 2025, as net inflows into equity-oriented schemes rose by 24% to ₹23,587 crore, according to data released by the Association of Mutual Funds in India (AMFI). This marked a sharp rebound from the ₹19,013 crore recorded in May. The rally in stock markets, along with steady economic indicators, supported investor sentiment. The Sensex gained over 3%, and the Nifty moved up by around 2.7% during the month. This helped boost mark-to-market gains across equity funds, lifting t

In a surprising market turn, Indian pharmaceutical stocks gained on July 9, 2025, despite fresh warnings from U.S. President Donald Trump about steep import tariffs on medicines. Trump hinted at a potential 200% duty on pharmaceutical imports into the U.S., sending ripples across the global drug industry. Trump stated that drug manufacturers would have a year to relocate their operations to the U.S., after which new tariffs would be enforced. "They're going to be taxed at a very, very high rate," he said, reaffirming his protectionist stance